disopyramide phosphate capsule
teva pharmaceuticals usa, inc. - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg - disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate is contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.
disopyramide phosphate capsule
avkare - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg - disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate is contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.
disopyramide phosphate er- disopyramide phosphate capsule, extended release
ethex - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - capsule, extended release - 150 mg - disopyramide phosphate extended-release capsules, usp are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. the extended-release capsules should not be used initially if rapid establishment of disopyramide plasma levels is desired. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate is contraindicated in the presence of cardiogenic shock, pre-existing second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hyperse
disopyramide phosphate capsule
mayne pharma inc. - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg - disopyramide phosphate capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate capsules are contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.
disopyramide phosphate capsule, gelatin coated
greenstone llc - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate is contraindicated in the presence of cardiogenic shock, preexisting second-or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.
disopyramide phosphate capsule
carilion materials management - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg - disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate is contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.
disopyramide phosphate capsules bp 100mg
generics uk limited station close, potters bar, herts, en6 1tl, united kingdom - disopyramide - capsule - disopyramide 100 mg - cardiac therapy
disopyramide phosphate capsule
mayne pharma commercial llc - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide phosphate capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate capsules are contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.
disopyramide phosphate capsule
actavis pharma, inc. - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg
disopyramide phosphate capsule
golden state medical supply inc. - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide phosphate capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. disopyramide phosphate capsules are contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.